Condition
ADPKD (Autosomal Dominant Polycystic Kidney Disease) clinical trials and research
As of November 12, 2026, Find a Trial lists 5 ADPKD (Autosomal Dominant Polycystic Kidney Disease) clinical trials that are recruiting, at sites in 5 countries (most in Germany (1), United States (1), China (1)). By phase: Phase 2 (2), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 5Countries
Newest ADPKD (Autosomal Dominant Polycystic Kidney Disease) clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| GV-100 first-in-human dose study in healthy adults | Phase 1 | Adelaide, South Australia | Recruiting | Aug 26, 2026 |
| Bempedoic Acid Therapy for ADPKD | Phase 2 | Baltimore, Maryland and 2 other locations | Recruiting | Dec 15, 2025 |
| JMKX003142 for rapidly progressive ADPKD | Phase 2 | Beijing, Beijing Municipality | Recruiting | Jan 30, 2025 |
| Decision-making support for choosing treatment in kidney disease | — | Anyang-si, Gyeonggi-do and 8 other locations | Recruiting | Oct 1, 2024 |
| Registry for patients with Autosomal Dominant Polycystic Kidney Disease treated with Tolvaptan | — | Müllheim, Baden-Wurttemberg and 11 other locations | Recruiting | Jul 14, 2015 |
All recruiting trials (5)
-
GV-100 first-in-human dose study in healthy adults
This early-stage study tests how GV-100 behaves and is tolerated in healthy adults to see how it might be used in people with ADPKD in the future.
-
Bempedoic Acid Therapy for ADPKD
This study tests whether bempedoic acid can help people with autosomal dominant polycystic kidney disease by slowing the progression of their kidney disease.
-
JMKX003142 for rapidly progressive ADPKD
This Phase 2 trial will test whether the oral medicine JMKX003142 is safe, well tolerated, and can slow disease progression in adults aged 18–55 with rapidly progressive ADPKD.
-
Decision-making support for choosing treatment in kidney disease
This study is testing a new mobile app that helps patients with a specific type of kidney disease make better treatment choices about a medication called tolvaptan.
-
Registry for patients with Autosomal Dominant Polycystic Kidney Disease treated with Tolvaptan
This study is collecting information from patients with Autosomal Dominant Polycystic Kidney Disease who are being treated with Tolvaptan to see how well the treatment works in real life.
Quick answers
How many ADPKD (Autosomal Dominant Polycystic Kidney Disease) clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in Germany (1 trial), United States (1 trial), China (1 trial), Australia (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.